• No results found

[PDF] Top 20 <p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>

Has 10000 "<p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>" found on our website. Below are the top 20 most common "<p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>".

&lt;p&gt;A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer&lt;/p&gt;

<p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>

... detects genomic alterations at extremely high coverage in 1053 cancer-related genes spanning a 4.6 Mb region of the genome, including base substitutions, insertions and dele- tions, copy number alterations, and ... See full document

13

Original Article High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer

Original Article High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer

... the expression of programmed cell death ligand 1 (PD-L1) and the survival of patients with small cell lung cancer (SCLC) who had ... See full document

8

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression

... for non-small-cell lung cancer ...(EGFR) mutations than in those with wild-type EGFR. We report here that an non-small-cell lung cancer patient ... See full document

5

Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

... grammed cell death protein 1 (PD-1). PD-1 is expressed by T cells and interacts with its ligands programmed cell death protein ... See full document

7

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy

... Abstract: Lung cancer is the leading cause of cancer death in males and the second leading cause of death in females ...worldwide. Non-small-cell lung ... See full document

14

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

... by programmed cell death protein-1 ...CTLA-4, PD-1 regulates immune activ- ity when effector T cell tissue infiltration ...cells, PD-1 is mainly ... See full document

15

CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment

CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment

... B; PD-1: Programmed cell death receptor-1; PD-L1: Programmed cell death ligand-1; NSCLC: Non- small-cell ... See full document

15

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

... anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibody has a good effect in the treatment of ... See full document

6

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

... Resected non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and urothelial carcinoma (UC) tissue samples (five samples per tumor type) were ... See full document

10

&lt;p&gt;BTLA Expression in Stage I&amp;ndash;III Non&amp;ndash;Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes&lt;/p&gt;

<p>BTLA Expression in Stage I&ndash;III Non&ndash;Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes</p>

... BTLA expression and clinical baseline characteristics (eg, age, sex, smoking status, his- tologic type, and stage) was analyzed with the chi-square ...the expression levels of BTLA with PD-1, ... See full document

10

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

... of programmed cell-death receptor (PD-1) and its associated ligand (PD-L1) have gained significant attention from the oncology ...community. PD-L1, ... See full document

6

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer

... the cancer-immunity cycle [19, ...T-lymphocyte protein 4 (CTLA4) and programmed cell death protein-1 (PD-1), are the best ...overall survival of ... See full document

12

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

... advanced non-small- cell lung cancer (NSCLC) [1, ...anti-programmed death (PD-1) antibody, has shown favorable antitumor efficacy in NSCLC patients ... See full document

5

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

... for cancer has been the targeting of immune check- point inhibitory molecules ...and ligand suppresses T cell receptor signaling, and limits immune ...molecule programmed cell ... See full document

11

Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer

Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer

... have declined significantly in developed countries, how- ever, the mortality is still high in developing countries. Approximately 90% of cervical cancer deaths occurred in low income and middle-income countries ... See full document

9

&lt;p&gt;Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study&lt;/p&gt;

<p>Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study</p>

... We isolated DNA from 5×10 6 PBMCs with the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer ’ s instructions. The concen- tration and purity of the isolated DNA were veri fi ed with the ... See full document

14

&lt;p&gt;Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer&lt;/p&gt;

<p>Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer</p>

... estimate PD-L1 expression in tumor cells for 168 patients with stage II ...univariate analysis, patients with high intraepithelial or stromal CD3+, CD8+, CD45RO+ and FOXP3+ TILs were ... See full document

16

The frequency of high PD-L1 expression is low in lung adenocarcinoma patients from Northeast Brazil

The frequency of high PD-L1 expression is low in lung adenocarcinoma patients from Northeast Brazil

... PD-L1 expression by immunohistochemistry (IHC) has emerged as an important factor, playing a major role in patient ...biomarker, PD-L1 helps to optimize therapy decisions by providing ... See full document

6

Checkpoint molecule PD-1-assisted CD8&lt;sup&gt;+&lt;/sup&gt; T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

Checkpoint molecule PD-1-assisted CD8<sup>+</sup> T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

... and non- specific staining with 3% (v/v) hydrogen peroxide and normal goat serum, the sections were incubated with anti-primary antibody overnight at ...anti-human PD-1 (ab52587, Abcam), and rabbit ... See full document

13

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer

... longer survival in low/moderate TMB plus negative PD-L1 subgroup compared to other two subgroups ...advanced lung cancer showing significant associa- tions between TMB and response to ... See full document

14

Show all 10000 documents...